Highlights

• A paper on the optimisation of Cynata’s Cymerus™ MSCs for treating coronary artery disease (CAD) has been featured in the peer reviewed Journal of Tissue Engineering and Regenerative Medicine.
• These exciting results suggest that Cymerus MSCs could play an important part in the management of CAD
• In Australia, over half a million people are affected with CAD. It was the single largest cause of death in 2020.
• The results published have been taken from the studies conducted under Cynata’s collaboration with the University of New South Wales, UNSW Sydney.
• The study showed modification of the cell culture matrix “primes” Cymerus MSCs and improves its pro-angiogenic and immunomodulatory properties

Cynata Therapeutics Limited (ASX:CYP),  an Australian clinical-stage stem cell and regenerative medicine company,  has announced the publication of a paper capturing the optimisation of Cymerus™ MSCs for the treatment of coronary artery disease (CAD) in Tissue Engineering and Regenerative Medicine, a highly respected peer reviewed Journal.

Cymerus™ is Cynata’s proprietary therapeutic stem cell platform technology. It has been designed and developed with the purpose to address the shortcomings of existing production methods of MSCs for therapeutic use. It can produce limitless quantities of therapeutic mesenchymal stem cells (MSCs), using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) at commercial scale from a single donation from a single donor.

Studying the use of Cymerus™ against CAD

A preclinical study was conducted by A/Prof Kristopher Kilian, Scientia Associate Professor at the School of Chemistry, and the School of Materials Science & Engineering in the UNSW Faculty of Science, following Cynata’s collaboration with the University of New South Wales, UNSW Sydney.

Image Source: © Arturszczybylo | Megapixl.com

The study demonstrated that modification of the cell culture matrix (the material on which the cells are grown) “primes” Cymerus MSCs. It improves the pro-angiogenic and immunomodulatory properties of Cymerus MSCs. It is believed that the therapeutic effects of MSCs in CAD are because of secretion of bioactive molecules. These molecules trigger the formation of new blood vessels (angiogenesis) in vitro and in vivo, as well as modulation of the immune system.

On whole, these effects are likely to enhance the therapeutic potential of Cymerus MSCs in treating CAD and related conditions. Moreover, the study results reflected that the priming effects were maintained after the cells were cryopreserved (frozen). This would enable storage of large batches of primed cells for clinical use.

Image: © 2022 Kalkine Media®

Management Commentary

Image: © 2022 Kalkine Media®

The paper has been published on the journal’s website. The print edition is expected to be available soon.